Hormonal Therapy for Breast Cancer: Focus on Fulvestrant

Linda Versea, NP, MSN, and Margaret Rosenzweig, PhD, CRNP-C, AOCN®

The understanding that estrogen has a role in the initiation and development of breast cancer is foundational to the understanding of breast cancer (Theriault, 2002). Understanding the role of hormones and increasing clinical sophistication with manipulation of hormonal agents against breast cancer has progressed slowly over the past 100 years (Theriault). Antiestrogen hormonal treatments have been important components of adjuvant and metastatic breast cancer treatment. Since the 1970s, tamoxifen was the mainstay of hormonal adjuvant breast cancer treatment in women with estrogen receptor-(ER-) positive breast cancer following adjuvant radiation and/or chemotherapy. Tamoxifen acts antagonistically toward estrogen by competing for binding sites. The drug originally was developed in 1969 as a possible contraceptive agent but demonstrated activity against advanced breast cancer in clinical trials (Powles, 1997). Tamoxifen’s efficacy in advanced breast cancer led to its use as adjuvant therapy (Carlson, 1997). Its efficacy is undisputed. Overall, for women with ER-positive primary breast cancer, tamoxifen allows an improved disease-free survival with a 47% reduction in the risk of recurrence and a 26% reduction in the risk of death (Early Breast Cancer Trialists’ Collaborative Group, 1998). However, tamoxifen is a selective ER modulator (SERM) and may act as an agonist in endometrial tissue and tumor cells that initially had been responsive to antiestrogen therapy (Terakawa, 2000). This may result in patients eventually becoming refractory to conventional antiestrogen therapies because of exhaustion of the ER sites or the growth of tamoxifen-stimulated ER-positive disease (England & Jordan, 1997). This exhaustion of ER sites can allow overgrowth of tissue (endometrial cancer) or lack of protective anticancer benefit (metastatic disease or breast cancer recurrence). This agonistic activity may allow tamoxifen to serve as a growth factor, rather than an inhibitor, for breast cancer cells (Terakawa). Tamoxifen also has a side-effect profile that includes a slightly increased risk for endometrial cancer, bone pain, and hot flashes. The drug creates an increased risk of cataracts, headache, hair thinning or loss, vaginal discharge, deep vein thrombosis, and menopause-like symptoms (Carlson, 1997).

Aromatase Inhibitors

As tamoxifen became integrated into general adjuvant and metastatic treatment protocols for women with breast cancer, a concurrent increase occurred in the understanding of the role of aromatases in the production of estrogen (Theriault, 2002). In postmenopausal women, estrogen is obtained from the conversion of androgen (from the adrenal glands) to estrogen. This process requires the enzyme aromatase (Goodman, 1988). Selective aromatase inhibitors (SAIs) block the conversion of androgen to estrogen by inhibiting the aromatase enzyme necessary for the conversion. SAI drugs can be used only in postmenopausal women. If used in premenopausal women, SAIs may cause an increase in gonadotropins and a subsequent increase in estradiol levels that may result in a breast cancer tumor flare or disease progression. To prevent this gonadotropic surge in premenopausal women, SAIs must be combined with a leutening hormone-releasing hormone agonist for chemical ovarian ablation. SAIs’ treatment role in breast cancer to date predominantly has been in metastatic breast cancer. Two studies, one in North America (Nabholtz et al., 2000) and one larger international trial (Bonnerette et al., 2000), established the equivalence, if not superiority, of anastrozole to tamoxifen in treatment of metastatic breast cancer (Terakawa, 2000). This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.

Submitted October 2002. Accepted for publication December 3, 2002. This article was written as a result of the Nurse Practitioner (NP) Special Interest Group’s mentoring program in which NPs are matched with NP mentors to implement a specific project. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Digital Object Identifier: 10.1188/03.CJON.307-311